Jade Biosciences
Jade Biosciences

Financials • Jade Biosciences

JBIO

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
0
-23
-12
0%
L
172
L
-167
-
-29
-0
190
-30
0
0
-
-
12/2022
0
-53
-12
0%
L
127
L
-129
-
-45
-0
0
-45
0
0
-
-
12/2023
0
-81
-12
0%
L
109
L
-122
-
-69
-0
46
-69
0
0
-
-
12/2024
0
-74
-12
0%
L
-47
L
38
L
-83
0
25
-83
0
0
-
-
12/2025
0
-114
-123
0%
L
333
L
-336
-
-115
-0
361
-115
0
0
-
-

To see all financials—including updated, you must be Premium.